{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:39:48Z","timestamp":1792269588311,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,16]]},"DOI":"10.7759\/cureus.114585","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:33:25Z","timestamp":1786865605000},"source":"Crossref","is-referenced-by-count":1,"title":["Non-suppurative Destructive Cholangitis After Avacopan Therapy in Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (MPO-ANCA)-Associated Glomerulonephritis: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Kensuke","family":"Terakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Uchitsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Sakurabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayumi","family":"Kawamura,","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Tochimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Saegusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071446","article-title":"ANCA-associated vasculitis: an update","volume":"10","author":"Almaani S","year":"2021","unstructured":"Almaani S, Fussner LA, Brodsky S, Meara AS, Jayne D. ANCA-associated vasculitis: an update. J Clin Med. 2021, 10:10.3390\/jcm10071446","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051724","article-title":"Current diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a review including a comparison of characteristics in Europe and Japan","volume":"14","author":"Horai Y","year":"2025","unstructured":"Horai Y, Kurushima S, Kawakami A. Current diagnosis and treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a review including a comparison of characteristics in Europe and Japan. J Clin Med. 2025, 14:10.3390\/jcm14051724","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.375","article-title":"Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification","volume":"85","author":"Haas M","year":"2014","unstructured":"Haas M, Rastaldi MP, Fervenza FC. Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. Kidney Int. 2014, 85:779-93. 10.1038\/ki.2013.375","journal-title":"Kidney Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1472234","article-title":"Avacopan in the treatment of ANCA-associated vasculitis","volume":"27","author":"Tesar V","year":"2018","unstructured":"Tesar V, Hruskova Z. Avacopan in the treatment of ANCA-associated vasculitis. Expert Opin Investig Drugs. 2018, 27:491-6. 10.1080\/13543784.2018.1472234","journal-title":"Expert Opin Investig Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-010-0178-4","article-title":"C5a promotes migration, proliferation, and vessel formation in endothelial cells","volume":"59","author":"Kurihara R","year":"2010","unstructured":"Kurihara R, Yamaoka K, Sawamukai N, et al.. C5a promotes migration, proliferation, and vessel formation in endothelial cells. Inflamm Res. 2010, 59:659-66. 10.1007\/s00011-010-0178-4","journal-title":"Inflamm Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen M","year":"2017","unstructured":"Chen M, Jayne DR, Zhao MH. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol. 2017, 13:359-67. 10.1038\/nrneph.2017.37","journal-title":"Nat Rev Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne DRW","year":"2017","unstructured":"Jayne DRW, Bruchfeld AN, Harper L, et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. JASN. 2017, 28:2756-67. 10.1681\/asn.2016111179","journal-title":"JASN"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne DR","year":"2021","unstructured":"Jayne DR, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021, 384:599-609. 10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich B","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, et al.. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024, 83:30-47. 10.1136\/ard-2022-223764","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.109674","article-title":"Avacopan-associated hepatotoxicity: clinical signal, liver injury patterns, and plausible mechanisms","volume":"18","author":"Herrera-Jim\u00e9nez LG","year":"2026","unstructured":"Herrera-Jim\u00e9nez LG, Arguedas-Chac\u00f3n S, Mora-Jim\u00e9nez J, Zavaleta-Monestel E. Avacopan-associated hepatotoxicity: clinical signal, liver injury patterns, and plausible mechanisms. Cureus. 2026, 18:e109674. 10.7759\/cureus.109674","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.01.1065","article-title":"Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option","volume":"7","author":"Gabilan C","year":"2022","unstructured":"Gabilan C, Pfirmann P, Ribes D, et al.. Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option. Kidney Int Rep. 2022, 7:1115-8. 10.1016\/j.ekir.2022.01.1065","journal-title":"Kidney Int Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae359","article-title":"Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study","volume":"64","author":"Gabilan C","year":"2025","unstructured":"Gabilan C, Belliere J, Moranne O, et al.. Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study. Rheumatology (Oxford, England). 2025, 64:2214-9. 10.1093\/rheumatology\/keae359","journal-title":"Rheumatology (Oxford, England)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.03.022","article-title":"Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"9","author":"Zonozi R","year":"2024","unstructured":"Zonozi R, Aqeel F, Le D, et al.. Real-world experience with avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int Rep. 2024, 9:1783-91. 10.1016\/j.ekir.2024.03.022","journal-title":"Kidney Int Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0340.C1","article-title":"Absence of glucocorticoids concomitant with avacopan and subsequent liver injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"51","author":"Uchida T","year":"2024","unstructured":"Uchida T, Fukui S, Iwamoto N, et al.. Absence of glucocorticoids concomitant with avacopan and subsequent liver injury in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2024, 51:1151. 10.3899\/jrheum.2024-0340.C1","journal-title":"J Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae689","article-title":"Drug-induced liver injury related to avacopan therapy","volume":"64","author":"Mori K","year":"2025","unstructured":"Mori K, Shirai T, Mutoh T, et al.. Drug-induced liver injury related to avacopan therapy. Rheumatology (Oxford, England). 2025, 64:2533-40. 10.1093\/rheumatology\/keae689","journal-title":"Rheumatology (Oxford, England)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-025-00456-4","article-title":"Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan","volume":"9","author":"Tagami G","year":"2025","unstructured":"Tagami G, Yamaguchi M, Sugiyama H, et al.. Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan. BMC Rheumatol. 2025, 9:8. 10.1186\/s41927-025-00456-4","journal-title":"BMC Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead285","article-title":"A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan","volume":"63","author":"Yamaguchi S","year":"2024","unstructured":"Yamaguchi S, Yamazaki M, Kido T, et al.. A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan. Rheumatology (Oxford, England). 2024, 63:120-2. 10.1093\/rheumatology\/kead285","journal-title":"Rheumatology (Oxford, England)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxad019","article-title":"Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"Kataoka H","year":"2023","unstructured":"Kataoka H, Tomita T, Nakanowatari M, Kondo M, Mukai M. Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis. Mod Rheumatol Case Rep. 2023, 7:444-7. 10.1093\/mrcr\/rxad019","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead561","article-title":"Comment on: A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan","volume":"63","author":"Shirota S","year":"2024","unstructured":"Shirota S, Shirai T, Mori K, et al.. Comment on: A case of vanishing bile duct syndrome during treatment of microscopic polyangiitis with avacopan. Rheumatology (Oxford, England). 2024, 63:149-50. 10.1093\/rheumatology\/kead561","journal-title":"Rheumatology (Oxford, England)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-024-06376-8","article-title":"A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis","volume":"39","author":"Nishino T","year":"2024","unstructured":"Nishino T, Tomori S, Haruyama M, Takahashi K, Mimaki M. A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis. Pediatr Nephrol (Berlin, Germany). 2024, 39:2919-22. 10.1007\/s00467-024-06376-8","journal-title":"Pediatr Nephrol (Berlin, Germany)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead509","article-title":"Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan","volume":"63","author":"Kojima K","year":"2024","unstructured":"Kojima K, Fukui S, Tanigawa M, et al.. Severe prolonged liver abnormality with jaundice during treatment for granulomatosis with polyangiitis with rituximab and avacopan. Rheumatology (Oxford, England). 2024, 63:101-3. 10.1093\/rheumatology\/kead509","journal-title":"Rheumatology (Oxford, England)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxae071","article-title":"Persistent liver injury following avacopan discontinuation in antineutrophil cytoplasmic antibody-associated vasculitis: A rare case of liver biopsy in the chronic phase of liver injury","volume":"9","author":"Yamaguchi H","year":"2025","unstructured":"Yamaguchi H, Fujii N, Shimizu H. Persistent liver injury following avacopan discontinuation in antineutrophil cytoplasmic antibody-associated vasculitis: A rare case of liver biopsy in the chronic phase of liver injury. Mod Rheumatol Case Rep. 2025, 9:163-7. 10.1093\/mrcr\/rxae071","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5043-24","article-title":"Vanishing bile duct syndrome caused by a treatment regimen including avacopan for microscopic polyangiitis","volume":"65","author":"Hishinuma M","year":"2026","unstructured":"Hishinuma M, Hasegawa M, Minatoguchi S, et al.. Vanishing bile duct syndrome caused by a treatment regimen including avacopan for microscopic polyangiitis. Intern Med. 2026, 65:1017-22. 10.2169\/internalmedicine.5043-24","journal-title":"Intern Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6273-25","article-title":"Avacopan-associated liver injury in Japanese patients with ANCA-associated vasculitis: clinical, genetic, and mechanistic perspectives","volume":"65","author":"Hishida E","year":"2026","unstructured":"Hishida E, Nagata D. Avacopan-associated liver injury in Japanese patients with ANCA-associated vasculitis: clinical, genetic, and mechanistic perspectives. Intern Med. 2026, 65:941-2. 10.2169\/internalmedicine.6273-25","journal-title":"Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae534","article-title":"The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain","volume":"64","author":"Draibe J","year":"2025","unstructured":"Draibe J, Espigol-Frigol\u00e9 G, Cid MC, et al.. The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain. Rheumatology (Oxford, England). 2025, 64:2019-26. 10.1093\/rheumatology\/keae534","journal-title":"Rheumatology (Oxford, England)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.07.007","article-title":"Avacopan in anti-neutrophil cytoplasmic autoantibodies-associated vasculitis in a real-world setting","volume":"9","author":"Zimmermann J","year":"2024","unstructured":"Zimmermann J, Sonnemann J, Jabs WJ, et al.. Avacopan in anti-neutrophil cytoplasmic autoantibodies-associated vasculitis in a real-world setting. Kidney Int Rep. 2024, 9:2803-8. 10.1016\/j.ekir.2024.07.007","journal-title":"Kidney Int Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001793","article-title":"Definition, diagnosis, and treatment of primary biliary cholangitis-autoimmune hepatitis (PBC-AIH) variant: an international expert Delphi consensus","author":"Gerussi A","year":"2026","unstructured":"Gerussi A, Sebode M, Nofit E, et al.. Definition, diagnosis, and treatment of primary biliary cholangitis-autoimmune hepatitis (PBC-AIH) variant: an international expert Delphi consensus. Hepatology. 2026, 10.1097\/HEP.0000000000001793","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328351d47f","article-title":"PharmGKB summary: very important pharmacogene information for CYP3A5","volume":"22","author":"Lamba J","year":"2012","unstructured":"Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics. 2012, 22:555-8. 10.1097\/FPC.0b013e328351d47f","journal-title":"Pharmacogenet Genomics"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000261","article-title":"Functional characterization of 40 CYP3A4 variants by assessing midazolam 1\u2032-hydroxylation and testosterone 6\u03b2-hydroxylation","volume":"49","author":"Kumondai M","year":"2021","unstructured":"Kumondai M, Guti\u00e9rrez Rico EM, Hishinuma E, et al.. Functional characterization of 40 CYP3A4 variants by assessing midazolam 1\u2032-hydroxylation and testosterone 6\u03b2-hydroxylation. Drug Metab Dispos. 2021, 49:212-20. 10.1124\/dmd.120.000261","journal-title":"Drug Metab Dispos"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1389","article-title":"Pharmacokinetic evaluation of the CYP3A4 and CYP2C9 drug-drug interaction of avacopan in 2 open-label studies in healthy participants","volume":"13","author":"Miao S","year":"2024","unstructured":"Miao S, Bekker P, Armas D, Lor M, Han Y, Webster K, Trivedi A. Pharmacokinetic evaluation of the CYP3A4 and CYP2C9 drug-drug interaction of avacopan in 2 open-label studies in healthy participants. Clin Pharmacol Drug Dev. 2024, 13:517-33. 10.1002\/cpdd.1389","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-022-00206-x","article-title":"3'mRNA sequencing reveals pro-regenerative properties of c5ar1 during resolution of murine acetaminophen-induced liver injury","volume":"7","author":"Gonther S","year":"2022","unstructured":"Gonther S, Bachmann M, Goren I, Huard A, Weigert A, K\u00f6hl J, M\u00fchl H. 3'mRNA sequencing reveals pro-regenerative properties of c5ar1 during resolution of murine acetaminophen-induced liver injury. NPJ Regen Med. 2022, 7:10. 10.1038\/s41536-022-00206-x","journal-title":"NPJ Regen Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030374","article-title":"The proinflammatory mediators C3a and C5a are essential for liver regeneration","volume":"198","author":"Strey CW","year":"2003","unstructured":"Strey CW, Markiewski M, Mastellos D, Tudoran R, Spruce LA, Greenbaum LE, Lambris JD. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med. 2003, 198:913-23. 10.1084\/jem.20030374","journal-title":"J Exp Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516402-non-suppurative-destructive-cholangitis-after-avacopan-therapy-in-myeloperoxidase-antineutrophil-cytoplasmic-antibody-mpo-anca-associated-glomerulonephritis-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:33:27Z","timestamp":1786865607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516402-non-suppurative-destructive-cholangitis-after-avacopan-therapy-in-myeloperoxidase-antineutrophil-cytoplasmic-antibody-mpo-anca-associated-glomerulonephritis-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.114585","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,16]]}}}